5.96
-0.1178(-1.94%)
Currency In USD
| Previous Close | 6.08 |
| Open | 6 |
| Day High | 6.47 |
| Day Low | 5.89 |
| 52-Week High | 26.62 |
| 52-Week Low | 3.85 |
| Volume | 359,788 |
| Average Volume | 767,361 |
| Market Cap | 213.74M |
| PE | -2.88 |
| EPS | -2.07 |
| Moving Average 50 Days | 17.34 |
| Moving Average 200 Days | 18.11 |
| Change | -0.12 |
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions
GlobeNewswire Inc.
Dec 18, 2024 2:00 PM GMT
Collaboration will leverage BioAge's differentiated human longevity data and platform and Novartis expertise in the biology of physical exercise to identify drug targets to treat diseases related to aging Novartis to pay up to $20M comprising upfront
BioAge Labs Announces Discontinuation of STRIDES Phase 2 Clinical Trial Evaluating Azelaprag in Combination with Tirzepatide for the Treatment of Obesity
GlobeNewswire Inc.
Dec 06, 2024 9:35 PM GMT
Decision follows observations of liver transaminitis without clinically significant symptoms in some subjects on azelaprag Company will evaluate data from patients enrolled to date and share updated plans for azelaprag in Q1 2025 In parallel to evalu
BioAge Labs to Present at Goldman Sachs “Year-Ahead” Catalyst Clinic
GlobeNewswire Inc.
Dec 05, 2024 9:30 PM GMT
RICHMOND, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human